EPS for Sarepta Therapeutics, Inc. (SRPT) Expected At $-0.57

June 13, 2018 - By James Guidry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It worsened, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Utd Svcs Automobile Association reported 0% stake. Bluecrest Capital Mgmt Ltd stated it has 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Neuberger Berman Lc accumulated 25,178 shares. State Of Wisconsin Board accumulated 59,000 shares or 0.01% of the stock. Guggenheim Cap Limited Liability Com accumulated 56,996 shares. Sei Invs reported 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Art Advsr Limited Liability reported 0.14% stake. Bankshares Of Nova Scotia accumulated 24,700 shares. Jabre Partners holds 5,900 shares. Citadel Ltd Co invested in 48,387 shares. Dupont Mgmt Corporation reported 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Mutual Of America Capital Management Limited Co stated it has 0% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). The Massachusetts-based Rhumbline Advisers has invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Dimensional Fund Advsrs Limited Partnership stated it has 111,965 shares. Envestnet Asset Mgmt, a Illinois-based fund reported 1,008 shares.

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock decreased 2.01% or $1.99 during the last trading session, reaching $96.77. About 2.87M shares traded or 131.80% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 14, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 16 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 27 analyst reports since January 3, 2018 according to SRatingsIntel. RBC Capital Markets initiated the shares of SRPT in report on Monday, January 22 with “Buy” rating. Nomura maintained the stock with “Buy” rating in Tuesday, June 5 report. The company was maintained on Friday, March 2 by Piper Jaffray. Piper Jaffray maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Friday, February 9 with “Buy” rating. As per Tuesday, March 13, the company rating was maintained by Leerink Swann. Oppenheimer downgraded the shares of SRPT in report on Thursday, May 3 to “Hold” rating. SunTrust maintained the shares of SRPT in report on Wednesday, March 7 with “Buy” rating. J.P. Morgan maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, February 21. J.P. Morgan has “Buy” rating and $75.0 target. The company was maintained on Friday, May 4 by Credit Suisse. Morgan Stanley maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Tuesday, March 6 with “Overweight” rating.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.34 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Nasdaq.com which released: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” on June 13, 2018, also Streetinsider.com with their article: “Sarepta Therapeutics (SRPT) Announces Long-term Strategic Manufacturing Partnership with Brammer Bio” published on June 13, 2018, Nasdaq.com published: “Biotech ETFs Are the Best Way to Play the Recovering Sector” on May 30, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Bizjournals.com and their article: “Biogen’s head of late-stage trials leaves for Sarepta” published on June 07, 2018 as well as Seekingalpha.com‘s news article titled: “Wave Life Sciences: What’s Cooking Behind This Innovator?” with publication date: May 23, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.